Low cardiac and left anterior descending coronary artery dose achieved with left-sided multicatheter interstitial-accelerated partial breast irradiation.

Brachytherapy 2019 Jan - Feb;18(1):50-56. Epub 2018 Sep 24.

Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI. Electronic address:

Purpose: Studies have shown that an additional mean dose of 1 Gy to the heart can increase the relative risk of cardiac events. The purpose of this study was to quantify the dose delivered to the heart and left anterior descending artery (LAD) in a series of patients with left-sided breast cancer (BC) or ductal carcinoma in situ treated with multicatheter-accelerated partial breast irradiation (MC-APBI) at a single institution.

Methods And Materials: Patients with left-sided BC or ductal carcinoma in situ treated consecutively from 2005 to 2011 with MC-APBI were retrospectively identified. Cardiac and LAD contours were generated for each patient. Cardiac dosimetry and distance to the planning target volume were recorded. Patient health records were reviewed and cardiac events were recorded based on Common Terminology Criteria for Adverse Events version 4.0.

Results: Twenty consecutive patients with left-sided BC treated with MC-APBI were retrospectively identified. Median followup was 41.4 months. Mean equivalent dose in 2 Gy fractions delivered to the heart and LAD were 1.3 (standard deviation: 0.7, range: 0.2-2.9) and 3.8 (standard deviation: 3.0, range: 0.4-11.3) Gy, respectively. There was an inverse linear relationship (R = 0.52) between heart-to-lumpectomy cavity distance and mean heart equivalent dose in 2 Gy fractions. One patient (5%) experienced symptomatic cardiac toxicity.

Conclusions: MC-APBI consistently delivers average doses to the heart and LAD that are similar to those achieved in most series with deep inspiration breath-hold and lower than free-breathing radiotherapy techniques. Distance from the heart to the lumpectomy cavity and the availability of other heart-sparing technologies should be considered to minimize the risk of cardiac toxicity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.08.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338487PMC
April 2019

Publication Analysis

Top Keywords

patients left-sided
12
distance heart
8
ductal carcinoma
8
carcinoma situ
8
breast irradiation
8
delivered heart
8
risk cardiac
8
cardiac events
8
standard deviation
8
heart lad
8
deviation range
8
dose fractions
8
retrospectively identified
8
equivalent dose
8
partial breast
8
situ treated
8
anterior descending
8
left anterior
8
mc-apbi retrospectively
8
cardiac
6

Similar Publications